The BALDER team aims identify new drug targets for Type 2 Diabetes together with their industry partner Novo Nordisk. To do so, they will develop novel statistical modelling approaches and use already existing genomic data.
On this page, you can find all of the news from ODIN, which is related to the BALDER project. If you are curious about more information, you are always welcome to contact Peter Sørensen, who is head of the BALDER project.
BALDER is short for "Bayesian AnaLysis of Diabetes for Enhanced biomarkeR and drug target identification".
